CTMI Cti Molecular Imaging - Common Stock (MM)

Mirada Solutions Announces Toshiba Medical Systems Corporation (Japan) as Partner in Fusion7D Sales in Japan OXFORD, England, June 24 /PRNewswire/ -- Mirada Solutions Ltd. (a subsidiary of CTI Molecular Imaging, Inc. (NASDAQ:CTMI)), leaders in software for molecular imaging, have today announced a distribution and development partnership with Toshiba Medical Systems Corporation (hereafter referred to as TMSC) of Japan, for distribution of the Fusion7D PET and image fusion platform in Japan as part of TMSC's nuclear medicine and PET workstation offering. Christian P. Behrenbruch Ph.D, President of Mirada Solutions commented, "We are truly pleased with the establishment of this relationship with TMSC. Not only does TMSC provide Mirada with powerful distribution capabilities in Japan, but also reflects a technology partnership that should have a dramatic impact on the positioning of PET technologies in the Japanese market. Image fusion and molecular applications will be key to success." Mr. Kenichiro Katsumata, Senior Vice President of TMSC, stated, "The commercial commencement of the relationship with Mirada took place at the Japanese Radiology Congress in April where we profiled the Fusion7D product in the Japanese market and made the decision to proceed with product integration. We feel that this technology platform and its product roadmap are an important addition to our PET product range and general software capabilities." This represents a significant distribution relationship for Mirada in one of the strongest emerging PET markets. The relationship between Mirada and TMSC encompasses a distribution aspect as well as a continuing commitment to provide advanced image analysis functions, fusion, tracer-specific tools and radiation therapy components as part of TMSC's PET offering. About Mirada Solutions: Mirada Solutions Limited, a wholly owned subsidiary of CTI Molecular Imaging, is a leading developer of software and analytical tools for medical imaging workstations, OEM imaging platforms and pharmaceutical research. Mirada's unique products aid in better detection, diagnosis and management of disease through the application of powerful algorithms, quantification tools and image analysis. Additional information is available at http://www.mirada-solutions.com/ . About CTI Molecular Imaging: CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, cardiac disease and neurological disorders. Additional information is available at: http://www.ctimi.com/ Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as "believe," "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward-looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements. CTI undertakes no obligation to update or revise any forward- looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003, Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. DATASOURCE: Mirada Solutions, Ltd. CONTACT: Clare F. Jones of Mirada Solutions Ltd., +44 1865 265 500; or Michael A. Lawless of CTI Molecular Imaging, Inc., +1-865-218-2000 Web site: http://www.mirada-solutions.com/ http://www.ctimi.com/

Copyright